Nearly 50 health care and consumer groups, including the AHA, voiced their support for the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act as it was reintroduced yesterday in the new Congress. “The CREATES Act will help ensure that brand-name pharmaceutical companies cannot take advantage of regulatory rules to forestall the competition that is essential for access and innovation,” the groups said in a letter to the bill’s sponsors, Sens. Chuck Grassley, R-Iowa, Patrick Leahy, D-Vt., Amy Klobuchar, D-Minn., and Mike Lee, R-Utah. “With its enactment, the CREATES Act will save patients and taxpayers $3.9 billion over 10 years, according to the Congressional Budget Office, by allowing lower-priced generic drugs to enter the market earlier. We also recognize and appreciate the commitment from Health and Human Services Secretary Alex Azar and Food and Drug Administration Commissioner Scott Gottlieb, M.D., on this important issue. Both have elevated awareness of brand manufacturer ‘gaming’ of FDA regulatory rules to deny would-be generic competitors the ability to purchase samples of brand-name drugs necessary to conduct the FDA-required testing and bring more affordable medicines to market.”

Headline
The AHA is now offering custom innovation summits — proven, high-impact workshops designed to convene health care leaders and co-…
Headline
America’s hospitals and health systems are deeply committed to providing high-quality, accessible and affordable care, AHA President and CEO Rick Pollack March…
Chairperson's File
Public
Leaders of rural hospitals face similar challenges as leaders of urban hospitals, but with an added degree of complexity, including recruiting staff,…
Headline
The AHA provided a statement Feb. 24 for a House Ways and Means Health Subcommittee hearing titled “Advancing the Next Generation of America’s Health Care…
Headline
The AHA commented today on the Centers for Medicare & Medicaid Services’ proposed rule on the Global Benchmark for Efficient Drug Pricing Model, or…
Headline
The Administration for Strategic Preparedness and Response Feb. 18 announced an investment that will focus on resolving a frequent shortage of oseltamivir,…